CYTOKINE RELEASE
SYNDROME EXPLAINED
The most common serious CAR-T side effect. Graded 1-4, peaking within the first week, managed with tocilizumab and corticosteroids at specialist centres.
analyticsAt a Glance
- check_circleCRS is the most common serious side effect of CAR-T therapy and bispecific antibodies
- check_circleSymptoms range from fever and fatigue to severe inflammation and organ failure in serious cases
- check_circleGraded 1โ4 by severity โ grade 3/4 CRS requires immediate intervention with tocilizumab or steroids
- check_circleCRS monitoring and management requires specialist oncology centre infrastructure
When the Immune Response Becomes the Challenge
When modified CAR-T cells find cancer and start attacking, they trigger a cytokine cascade โ immune signalling proteins released in large quantities, rapidly. This is the therapy working. The problem is scale. The immune system rarely activates at this magnitude normally.
โCRS is, in an unusual sense, evidence that the therapy is working โ it signals CAR-T cells are finding their targets.โ
CRS Grading System
| Grade | Symptoms | Management |
|---|---|---|
| Grade 1 | Fever >38ยฐC | Antipyretics, supportive care |
| Grade 2 | Fever + hypotension (responds to fluids) or low O2 | Tocilizumab introduced |
| Grade 3 | Hypotension requiring vasopressor(s) or high-flow O2 | Tocilizumab + corticosteroids; ICU monitoring |
| Grade 4 | Life-threatening organ dysfunction | Urgent intensive intervention |
CRS Timing
- 1-3 daysMedian onset after infusion
- 7 daysTypical peak window
- 14 daysMost CRS resolved by
Frequently Asked Questions
About CRS
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Understanding CRS Before Your CAR-T Treatment?
A specialist consultation explains what monitoring protocols look like at your treating centre and how your health profile affects risk.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.